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Abstract
Background: Protein kinase C regulates various cellular processes including cell proliferation, cell adhesion,
apoptosis, angiogenesis, invasion, and metastasis. Activation of different PKC isozymes results in distinct cellular
responses. Novel PKCs are mainly involved in apoptotic process. Atypical PKC subfamily plays a critical role in cell
proliferation and apoptosis, cell differentiation and motility. However, Atypical PKCs show contradictory regulation
in different tissues or cancer cells. The mechanism of diversified effects is not well explored. Antioxidant ellagic acid
shows hepatoprotective, anti-carcinogenic and anti-mutagenic properties. Present study is focused to analyze the
effect of ellagic acid on novel and atypical isozymes of PKC in regulation of PKC-mediated apoptosis in liver of
lymphoma bearing mice. Implication of ellagic acid treatment to DL mice was analyzed on caspase-3 mediated
apoptosis via PKCδ induced activation; and on maintenance of adequate supply of energy during cancer growth.
Methods: 15–20 weeks old adult DL mice were divided into four groups (n = 6). Group 2, 3, 4 were treated with
different doses of ellagic acid (40 mg/kg, 60 mg/kg and 80 mg/kg bw). The mice were sacrificed after 19 days of
treatment and liver was used for study. The effect of ellagic acid was determined on expression of novel and
atypical PKC isozymes. Apoptotic potentiality of ellagic acid was checked on activities of caspase-3 and PKCδ in
terms of their catalytic fragments. Aerobic glycolysis was monitored by LDH activity, especially activity of LDH A.
Results: Ellagic acid treatment caused up regulation of expression of almost all novel and atypical PKC isozymes.
Activities of PKCδ and caspase-3 were enhanced by ellagic acid, however activities of total LDH and LDH-A were
inhibited.
Conclusion: The results show that ellagic acid promotes apoptosis in lymphoma bearing mice via novel and
atypical PKCs which involves PKCδ induced caspase-3 activation; and inhibition of glycolytic pathway.
Keywords: PKC isozymes, Apoptosis, LDH-A, Anaerobic glycolysis
Background
Different isozymes of PKC are implicated in regulation of
cellular processes including cell proliferation, differenti-
ation, malignant transformation and apoptosis [1–3].
Members of PKC family catalyze either pro- or anti-
apoptotic processes depending on the isoforms and cellu-
lar context. Previously we have reported over-expression
of classical PKCs in lymphoma bearing mice which is
known to favour cell proliferation [4]. Novel PKCs are
mainly involved in apoptotic process [5]. PKCδ deficient
mouse is reported to suppress apoptosis in response to
chemotherapeutic drug [6]. Ionising radiation induces
apoptosis via activation of PKCδ in Jurkat T cells [7]. In-
creased expression and/or activation of PKCή has been
associated with cell cycle arrest in a various kinds of cell
lines as well as in a variety of normal epithelial and non
epithelial tissues [8]. Atypical Isozymes of PKC subfamily
including PKCζ and PKCι, are involved in different cellular
processes like cell proliferation, apoptosis and differenti-
ation. They are found either up regulated or down regu-
lated in different cancers. PKCζ is reported to be involved
in suppressing melanoma cell migration [9]. However,
PKCι can function as an oncogene [10]. Studies on PKCι
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have revealed a critical role of PKCι at multiple stages of
tumorigenesis, including tumor initiation, progression,
and metastasis. However, little is known about its role in
apoptosis.
Murine Dalton’s lymphoma is a Non Hodgkin’s trans-
plantable T cell lymphoma which can spread beyond the
lymphatic system to almost any part of the body including
liver, bone marrow and spleen. Secondary lymphoma
growth in liver has been confirmed earlier in our labora-
tory by histopathological analysis showing impaired shape
of hepatocytes with large nucleus, increased sinusoids
with infiltration of a large number of leucocytes [11]. Liver
of DL mice was found larger and softer as compared to
normal ones indicating malignant growth.
Apoptosis or programmed cell death is a physiological
process through which cell population regulates normal
growth and morphogenesis. Alterations of various signal-
ing pathways may result in deregulation of apoptosis, lead-
ing to cancer. Continuous increase in cell population is
characteristic feature of any cancer which may occur due
to defect in cell cycle controlling mechanism or in any
apoptotic pathway. Caspase-3 is a member of the caspase
family that plays a central role in the execution of apop-
totic program. The enzyme is involved in both extrinsic as
well as extrinsic pathways of apoptosis, targeting various
mediators as confirmed by both in vitro and in vivo stud-
ies [12]. Caspase-3 is activated only in the form of cleaved
p17 peptide. PKCδ phosphorylates and cleaves caspace-3
to its active fragment i.e. p17 peptide and is itself a target
for caspases. Caspase-3 targets the cleavage of PKCδ
resulting into its constitutively active catalytic fragment
(CF) which is involved in apoptosis [13, 14].
High energy requirement for cancer growth is met with
aerobic glycolytic metabolism. Alternation in cellular me-
tabolism to anaerobic state is most consistent hallmark of
cancer [15]. LDH-A is the main isozyme of glycolytic
enzyme LDH, kinetically favouring conversion of pyruvate
to lactate under aerobic and hypoxic conditions. De-
creased activity of LDH-A is reported to reduce cellular
transformation, and markedly delayed tumor formation
indicating that LDH-A is important for tumor initiation
[16]. Therefore decreased activity of LDH is expected to
suppress survival of cancerous cells by depletion of high
energy requirement.
The link between different phytochemicals and their
cancer preventive role has been widely investigated. Ellagic
acid, a polyphenolic compound found in berries, fruits
and nuts is reported to possess growth-inhibiting and
apoptotic activities in different cancer cell lines in vitro
[17, 18]. We have earlier reported suppression of lymph-
oma growth in mice by ellagic acid [4, 19]. The present
study is aimed to investigate molecular signaling pathway
involved in anti carcinogenic activity of ellagic acid via
modulation of apoptotic process and its correlation with
novel and atypical isozymes of PKC. Further, impact of
ellagic acid on glycolytic metabolism is analyzed in liver of
lymphoma bearing mice.
Methods
All the chemicals used in experimental work were of
analytical and molecular biology grade. TEMED, 2-
thiobarbituric acid, ellagic acid and SDS were purchased
from Himedia. Reagents for RNA isolation, RT-PCR,
antibody of β-actin, PKC δ, caspase-3 and PMSF were
purchased from Sigma Aldrich, Ribonuclease inhibitor,
random hexamer, 100 bp Plus DNA ladder; and Reverse
Transcriptase from Fermentas Life sciences, Polyclonal
HRP-conjugated goat anti-rabbit IgG from Bangalore
Genei, ECL super signal Western pico kit from Pierce
respectively.
Induction of lymphoma
AKR strain mice were used for the study as they are
much more susceptible to lymphoma and have a short
life span (approximately 18 months). The study was ap-
proved by Animal Ethical Committee of Banaras Hindu
University. Mice were bred and maintained as per the
norms of Animal Ethical Committee of Institute, at 25 ±
2 °C under 12 hrs light/dark schedule with ad libitum
supply of standard mice feed and drinking water.Dalton’s
lymphoma ascites cells were transplanted in adult male
mice through serial transplantation by intra peritoneal
(i.p.) injection of about 1 × 106 viable ascites tumour
cells in 1 ml of phosphate buffer saline (PBS) per mouse,
as described previously [19]. Development of DL was
confirmed by abdominal swelling and increased body
weight, which were visible clearly on 10–11 day post
transplantation.
Administration of ellagic acid
DL mice were divided into four groups (n = 6). Three
groups were treated with different doses of ellagic acid
(40 mg/kg, 60 mg/kg and 80 mg/kg body weight)
dissolved in 0.2 % DMSO as a vehicle. Treatment was
started from the next day of ascites cell transplant. Ellagic
acid was given by gavage feeding at 24 h intervals for 15
consecutive days. One DL control group was given only
vehicle. All the groups of mice were sacrificed on day 19
of DL transplantation by cervical dislocation. Liver was
excised immediately after sacrificing the animal and
washed in chilled normal saline. Liver of all animals of
one group was pooled and mixed by chopping aseptically
at 4 °C for average result. Collected tissue was used imme-
diately or preserved at −80 °C for further study.
Assay of Lactate Dehydrogenase (LDH)
Assay of total LDH was performed in liver of mice accord-
ing to the method of Schwartz and Bodansky [20] with
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minor modifications [21]. The principle of detection is
based on spectrophotometrically monitored conversion of
NADH to NAD+ in a pyruvate utilizing reaction at
340 nm.
Activity of LDH-A was analyzed by activity gel assay.
Proteins were separated on 7.5 % resolving gel containing
4.5 % stacking gel using Tris/ glycine, pH 8.3 electrophor-
esis buffer; and stained by activity staining with solution
containing 0.25 M Phosphate buffer (pH 7.4), 10 mM lith-
ium lactate, 15 mM NAD+, 1.25 mM NBT, 5 mM NaCN,
5 mM MgCl2, 1.25 mM, and 3.3 mM phenazine metho-
sulfate in dark for 30–45 min at RT. The reaction was
stopped after appearance of desired bands by adding
fixative solution (45 % methanol and 10 % acetic acid).
The level of LDH-A was analyzed by densitometry scan-
ning of appeared band on gel using Alpha image analyzer
software.
RNA Isolation and RT-PCR
Expression of different genes was studied by semiquantita-
tive RT-PCR. Total RNA from each group of tissue was
isolated separately using TRI reagent (Sigma Aldrich,
Catalogue Number-T9424) as per the manufacturer’s
instruction.
DNase treatment was carried out on total RNA using
TURBO DNA-Free™ Kit I (DNase I, Ambion). Reverse
transcription of 2 μg RNA was done by using c-DNA syn-
thesis kit (Revert AidTM First Strand c-DNA synthesis Kit,
Fermentas Life Science, Catalogue Number-K1621), ac-
cording to manufacturer’s standard protocol. cDNA was
amplified using specific primers supplied by Metabion
International AG (Table 1). Amplification was per-
formed in a DNA Thermal Cycler (Applied Biosystem)
under a three-step temperature cycle. The band inten-
sity of amplified products in the gel was visualized,
photographed and analyzed using Gel Doc System
(Alpha InnotechEC). Further, band intensity was nor-
malized with β-actin.
Western blot analysis
Catalytic activity of PKCδ and caspase-3 were determined
by Western blot analysis. Equal amount of protein from
each sample was separated in 10 % SDS–PAGE and trans-
ferred to the PVDF membrane overnight at 4 °C. Mem-
brane was blocked in 5 % non-fat milk in PBS (pH 7.4) for
2 h ar RT. The blot was then incubated with rabbit anti-
caspase-3(Product number C8487) or rabbit anti- PKCδ
(AB-645; Product number SAB-4300539) in 1 % BSA and
0.05 % Tween-20 in PBS (pH 7.4). Blot was washed and
incubated with HRP-conjugated goat anti-rabbit IgG in
PBS (pH 7.4) containing 1 % BSA and 0.05 % Tween-20
for 2 h at RT. Immunoreactive proteins were detected
with ECL super signal kit (Pierce Biotechnology) in X-ray
film. The same blot was used for the detection of β-actin
as internal control. Band density values were normalized
with β-actin.
Table 1 Primer pairs and conditions of PCR
Genes with accession no Sequences of primer pairs (F: forward, R: reverse) PCR condition (annealing) No. of cycles Amplicon Size (bp)
PKCδ F: 5′-AGGCCGTGTTATCCAGATTG-3′ 58 °C-40 s 27 426
(NM_011103.3) R: 5′-CGGCCGATAATCTTGTCAAT-3′
PKCη F: 5′-CAAACTGCGGGGTGAATG-3′ 54 °C-30 s 27 437
(NM_008856.3) R: 5′-TCCGTTCACAAACTCCATGA-3′
PKCε F: 5′-ACGAGTGTTCAGGGAGCGTA-3′ 58 °C-45 s 27 331
(NM_011104.3) R: 5′-CGTGGGGACCTTGTAGTTGT-3′
PKCζ F: 5′-TCAAGTGGGTGGACAGTGAA-3′ 57 °C-45 s 30 284
(NM_008860.3) R: 5′-CCATATCCTTTCGCTGCACT-3′
PKCι F: 5′-GGGACTTTGCAGTGAGGTTC-3′ 56 °C-40 s 28 192
(NM_008857.3) R: 5′-CGCTCTGGTACACATGGAAA-3′
PKCθ F- 5′-CCAGAAAAAGCCAACCATGT-3′ 57 °C-30 s 35 521
(NM_008859.2) R- 5′-TGGTTTCTCGGCTATTGATTG-3′
Caspase-3 F- 5′- CAAAGCGCAGTGTCCTGCGG-3′ 61 °C-45 s 28 546
(NM_009810.3) R- 5′- ACCCCGGCAGGCCTGAATGA-3′
LDH-A F- 5′-ATGCACCCGCCTAAGGTTCTT-3′ 55 °C-30 s 28 103
(NM_010699.2) R- 5′-TGCCTACGAGGTGATCAAGCT-3′
β-actin F: 5-GTGGGCCGCCCTAGGCACCAG-3′ 56 °C-45 s 27 539
(NM_007393.3) R: 5-TCTTTGATGTCACGCACGATTTC-3′
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Statistical analysis
All experiments were repeated three times and statistical
analysis was performed using SPSS version 11.5 software
with one-way analysis of variance (ANOVA) followed
by Tukey test. Values are expressed as mean ± SD. A
value p < 0.05 was taken as statistically significant from DL.
Results
Ellagic acid up regulates the expression of novel PKC
isozymes
The expressions of all four novel isoforms were down reg-
ulated in DL mice liver as compared to normal. However,
ellagic acid treatment to DL mice was found to cause up
regulation in mRNA transcription of all isozymes as com-
pared to untreated DL mice. Up regulation in expression
of PKCδ, PKCε, PKCή was observed approximately up to
1.2 folds, 1.34 folds and 1.37 folds respectively with a dose
of 60 mg ellagic acid. However, 80 mg dose increased the
expression of all novel PKC isozymes (δ, ε, ή and θ) upto
1.3 folds, 1.36 folds, 1.3 folds and 1.24 folds respectively
(Fig. 1).
Ellagic acid up regulates activity of PKCδ
The effect of ellagic acid was analyzed on the activity of
pro-apoptotic isozyme PKCδ. The activity was measured
in terms of the level of catalytic fragment (CF) by Western
blot analysis. Catalytically active fragment (CF) of PKCδ
was found to be down regulated significantly (p < 0.05) in
DL mice liver as compared to normal. The dose of 60 mg
and 80 mg ellagic acid increased its level significantly upto
1.64 and 1.42 folds respectively (Fig. 2).
Ellagic acid promotes expression and activation of
caspase-3
The implication of ellagic acid on apoptosis was further
checked by testing the apoptotic enzyme caspase-3. The
mRNA expression of caspase-3 was down regulated in DL
mice as compared to normal, which was significantly up
regulated up to 1.3 folds with 80 mg dose of ellagic acid
treatment (Fig. 3). Caspase-3 is activated only in the form
of cleaved p17 peptide. Cleavage of caspace 3 was low to
about 62 % in DL mouse, as tested by level of cleaved form
(p17); however treatment with ellagic acid to DL mouse
promotes activation of caspace 3. The dose of 60 and
80 mg/kg body weight of ellagic acid significantly in-
creased the activation approximately up to 133 and 112 %
respectively (Fig. 4).
Ellagic acid increases the expression of atypical PKC
isozymes
Following a similar trend of variation of novel isozymes of
PKC, the expressions of atypical isozymes were also found
to be decreased in DL mice liver as compare to normal;
and were significantly enhanced by approximately 40 %
with the doses of 40 and 60 mg ellagic acid (Fig. 5).
Fig. 1 Effect of ellagic acid on gene expression of novel PKC
isozymes in liver of DL mice Values are expressed as mean ± SD,
* indicates that groups differ significantly from DL at the level of
significance p < 0.05 using one way ANOVA followed by Tukey test.
N, DL, DLT40, DLT60 and DLT80 represents normal, Dalton’s
lymphoma bearing, and Dalton’s lymphoma bearing mice treated
with 40, 60, 80 mg/kg body weight of ellagic acid respectively.
EA – Ellagic acid, M- Marker
Fig. 2 Effect of ellagic acid on level of catalytic fragment of PKCδ.
Values are expressed as mean ± SD, *indicates that groups differ
significantly from DL at the level of significance p < 0.05 using one
way ANOVA followed by Tukey test. N, DL, DLT40, DLT60 and DLT80
represents normal, Dalton’s lymphoma bearing, and Dalton’s
lymphoma bearing mice treated with 40, 60, 80 mg/kg body weight
of ellagic acid respectively
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Ellagic acid regulates anaerobic metabolism
Glycolytic metabolism was monitored in terms of total
activity of LDH as well as activity of anaerobic isozymes
LDH-A. Total activity of LDH was analyzed by spectro-
photometric assay, which was found to be approximately
3 fold higher in DL mice liver as compared to normal.
The dose of 60 and 80 mg ellagic acid was found to
decrease the activity approximately by half (Fig. 6). Activ-
ity of LDH-A measured by activity gel assay, was approxi-
mately double in DL mice liver as compared to normal
and dose of 80 mg ellagic acid significantly inhibited the
activity (Fig. 7a). Following the similar variation pattern,
Fig. 3 Effect of ellagic acid on gene expression of caspase-3.
Values are expressed as mean ± SD, * indicates that groups differ
significantly from DL at the level of significance p < 0.05 using one
way ANOVA followed by Tukey test. N, DL, DLT40, DLT60 and DLT80
represents normal, Dalton’s lymphoma bearing, and Dalton’s lymphoma
bearing mice treated with 40, 60, 80 mg/kg body weight of ellagic
acid respectively
Fig. 4 Effect of ellagic acid on activity of caspase-3 in terms of its
p17 fragment by Western blot analysis in liver of mice. Values are
expressed as mean ± SD, * indicates that groups differ significantly
from DL at the level of significance p < 0.05 using one way ANOVA
followed by Tukey test. N, DL, DLT40, DLT60 and DLT80 represents
normal, Dalton’s lymphoma bearing, and Dalton’s lymphoma
bearing mice treated with 40, 60, 80 mg/kg body weight of ellagic
acid respectively
Fig. 5 Effect of ellagic acid on gene expression of atypical PKC
isozymes. Values are expressed as mean ± SD, *indicates that groups
differ significantly from DL at the level of significance p < 0.05 using
one way ANOVA followed by Tukey test. N, DL, DLT40, DLT60 and
DLT80 represents normal, Dalton’s lymphoma bearing, and Dalton’s
lymphoma bearing mice treated with 40, 60, 80 mg/kg body weight
of ellagic acid respectively
Fig. 6 Effect of ellagic acid on total activity of LDH. Values are
expressed as mean ± SD, *indicates that groups differ significantly
from DL at the level of significance p < 0.05 using one way ANOVA
followed by Tukey test. N, DL, DLT40, DLT60 and DLT80 represents
normal, Dalton’s lymphoma bearing, and Dalton’s lymphoma
bearing mice treated with 40, 60, 80 mg/kg body weight of ellagic
acid respectively
Mishra and Vinayak BMC Complementary and Alternative Medicine  (2015) 15:281 Page 5 of 8
the expression of LDH-A in liver of DL mice was also ele-
vated up to about double as compared to normal and
ellagic acid treatment down regulated the expression sig-
nificantly in a dose dependent manner (Fig. 7b).
The dose of 80 mg ellagic acid/kg body weight was
found to be optimal dose.
Discussion
Anti carcinogenic property of ellagic acid has been estab-
lished by us in DL mice by decrease in tumor size (volume
of ascites fluid), decrease in viability and proliferation of
ascites cells as well as increase in longevity of DL mice.
Antioxidant phytochemicals are proposed to act through
intracellular signaling pathways [22]. In the present study
we tested the hypothesis that anti carcinogenic property
of polyphenol ellagic acid could be mediated by enhancing
apoptosis in cancerous tissue. We have tested here
whether ellagic acid modulates novel and atypical izso-
zymes of PKC, as these isozymes are associated with apop-
totic stimulation. The implication of ellagic acid on
apoptotic process is further checked by monitoring
expression and activity of caspase-3. In addition, the status
of glycolytic metabolism was analyzed to assess the avail-
ability of high energy necessary for lymphoma growth.
Novel PKC is reported to be mainly involved in apop-
tosis. Recently, activation of PKCδ signaling is reported to
induce apoptosis in hepatocellular carcinoma cells [23].
Epigenin, a plant product activates PKCδ and induces
apoptosis in leukemia cells [24]. Over expression of PKCε
is reported to cause apoptosis in human prostate cancer
cells [25]. Recent evidences indicate that proteolytically
cleaved, activated form of PKCε regulates apoptosis. PKCθ
has also been reported to be involved in chemical (TCDD)
induced apoptosis of lymphoblastic T cell line, L-MAT
[26] and in neuroblastoma and Jurkat cells [27]. Reduced
expression of PKCή has been shown in human liver can-
cer [28]. Our finding of decreased expression of all the iso-
zymes of novel PKC (PKCδ, PKCε, PKCθ PKCή) in liver
of lymphoma bearing mice, and their up regulation by
ellagic acid treatment suggest apoptosis-inducing activity
of ellagic acid. The ubiquitously expressed PKCδ is major
isoform of novel PKC which has been shown to regulate
apoptosis and survival in different cells [29]. PKCδ is acti-
vated under different stimuli and cleaves caspace-3 produ-
cing its active fragment i.e. p17 peptide [14]. Moreover,
caspase-3 cleaves PKCδ and leads to generation of its
catalytically active fragment (CF) which is implicated in
the apoptotic function [30]. Decreased level of both the
catalytically active fragment of PKCδ in DL mice liver and
significant improvement in the level of the active fragment
by ellagic acid supports cancer preventive role of ellagic
acid via apoptotic stimulation by a positive feedback
stimulation of the activity of both PKCδ and caspase-3.
The result suggests a novel link between the activation
of PKCδ and the induction of apoptosis by ellagic acid.
Our result also confirms decreased expression of caspase-
3 in DL mice liver. Caspase-3 expression is reported to be
variable in a variety of non-Hodgkin’s and Hodgkin’s
lymphomas [31]. The mRNA and protein expressions of
caspase-3 are reported to be undetectable in breast and
cervical cancers and substantially low expression in ovar-
ian cancer and in prostate tumors [32]. We demonstrate
that ellagic acid induces PKCδ activity in association with
proteolytic activation of caspase-3, as indicated by en-
hanced level of active fragment of caspase-3. Proteolytic
cleavage of PKCδ by caspase-3 results in persistent activa-
tion of the PKC which might initiate a myriad of vital
signalling cascades for apoptosis [33]. Thus the results
support positive feedback activation loop between PKCδ
and caspase-3 during apoptosis as suggested earlier [30].
Fig. 7 Effect of ellagic acid on activity and expression of LDH- A. a In gel assay showing LDH-A activity. b RT-PCR analysis showing mRNA
expression of LDH-A. Values are expressed as mean ± SD, * indicates that groups differ significantly from DL at the level of significance p < 0.05
using one way ANOVA followed by Tukey test. N, DL, DLT40, DLT60 and DLT80 represents normal, Dalton’s lymphoma bearing, and Dalton’s
lymphoma bearing mice treated with 40, 60, 80 mg/kg body weight of ellagic acid respectively
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Atypical PKCs regulate various cellular processes like
cell proliferation, apoptosis and cell differentiation. We
demonstrate decreased expression of both isoforms of
atypical PKCs - PKCζ and PKCι in liver of lymphoma
bearing mice and their increase after ellagic acid treat-
ment. However, the role of PKCζ in tumorigenesis is
controversial. PKCζ is reported to suppress apoptosis by
directly inhibiting and interacting Bax pro apoptotic activ-
ity in lung carcinoma cells [34], as well as to induce
apoptosis in ovarian cancer cells by phosphorylation of
the kinase [35]. PKCζ has been reported to repress
interleukin-6 promoter and impairs tumorigenesis in vivo
[36]. Similarly, PKCι is involved in carcinogenesis of
several cancers [37]. PKCι is recently reported to mediate
lipid-induced apoptosis of human coronary artery endo-
thelial cells [38]. Our result supports anti carcinogenic
action of PKCζ and PKCι.
Earlier we have reported that ellagic acid regulates the
classical isozymes involved in cell proliferation via NF-kB
signalling [4]. In the present study, the expression of novel
and atypical isozymes are found to be regulated in oppos-
ite way to classical isozymes by ellagic acid treatment,
suggesting that novel and atypical PKCs are involved in
apoptosis of lymphoma induced by ellagic acid.
Tumor cells exhibit profound genetic, biochemical and
histological differences with respect to the original, non
transformed cells types. A distinctive feature of tumor
cells is the alteration of their carbohydrate metabolism to
aerobic glycolytic pathway. Warburg’s effect demonstrates
necessity of aerobic glycolysis or glycolytic metabolism to
provide sufficient energy for maintenance of cancer
growth [39]. Therefore, activation of anti survival pathway
in ellagic acid treated mice should be under regulation of
glycolytic metabolism.
In addition, tumor micro environment is turned acidic
due to production of lactic acid during glycolytic pathway.
Acidic medium stimulates disruption of adherence junc-
tions, metastatic potential, proteinase activity and drug re-
sistance [40]. LDH-A is one of the main isoforms of LDH
which catalyses the conversion of pyruvate to lactate even
under hypoxic condition of tumor microenvironment.
The activity and expression of LDH-A is frequently
increased in different cancers. Therefore LDH activity is
considered as biochemical marker of cancer growth. De-
pletion of energy and growth promoting substrates due to
decline in glycolytic efficiency could act as an inducer of
apoptosis in the tumor cells. Decreased LDH activity,
especially LDH-A activity in ellagic acid treated DL mice
ensures inhibition of adequate supply of energy as well as
maintenance of normal pH, resulting into poor survival of
cancer cells and stimulation of apoptosis. In accordance to
our result, aqueous extracts of antioxidant S. anacardium
is reported earlier by us to down regulate anaerobic
metabolism by inhibiting the activity of LDH-A in liver of
lymphoma bearing mice [41]. Induced apoptosis and
decreased glycolytic metabolism in DL mice, after ellagic
acid treatment is correlated with its cancer preventive
role. We have earlier demonstrated anti carcinogenic
activity of ellagic acid in DL mice in terms of morphologic
changes, as well as by increase in longevity, decrease in
volume of ascites fluid accumulation in peritoneum and
by decrease in cell proliferation with increased survival
[4]. The overall result supports our earlier findings of
cancer preventing role of ellagic acid in ascites cells of
lymphoma bearing mice [42]. Thus ellagic acid prevents
primary lymphoma growth in ascites fluid, as well as
secondary growth in liver of DL mice by promoting apop-
tosis and inhibiting energy production by glycolytic
metabolism.
Conclusion
The present study demonstrates anti carcinogenic activity
of ellagic acid by inducing apoptosis in liver of DL mice
via novel and atypical PKCs, especially PKCδ in associ-
ation with caspase-3 and also by blocking the energy
metabolism.
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